Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard D Kim

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|April 8, 2021
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancerDae Won Kim, Elaine Tan, Jun-Min Zhou, et al.
American Journal of Clinical Oncology|February 7, 2020
Determining Optimal Follow-up for Patients With Anal Cancer Following ChemoradiationMarissa L Frazer, George Yang, Seth Felder, et al.
Cancer|June 1, 2016
Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancersNishi Kothari, Jamie K Teer, Andrea M Abbott, et al.
JAMA Network Open|March 20, 2025
Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal CancerShahla Bari, Marco Matejcic, Richard D Kim, et al.
American Journal of Clinical Oncology|November 3, 2015
Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical TrialsAaron Denson, Nancy Burke, Georgine Wapinsky, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2022
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancerRichard D Kim, Bence P Kovari, Maria Martinez, et al.
JAMA Network Open|June 26, 2023
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal CancerLingbin Meng, Ram Thapa, Maria G Delgado, et al.
JAMA Oncology|May 1, 2020
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerRichard D Kim, Vincent Chung, Olatunji B Alese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
Cancers|June 13, 2025
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter StudyMaen Abdelrahim, Abdullah Esmail, Richard D Kim, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|April 8, 2021
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancerDae Won Kim, Elaine Tan, Jun-Min Zhou, et al.
American Journal of Clinical Oncology|February 7, 2020
Determining Optimal Follow-up for Patients With Anal Cancer Following ChemoradiationMarissa L Frazer, George Yang, Seth Felder, et al.
Cancer|June 1, 2016
Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancersNishi Kothari, Jamie K Teer, Andrea M Abbott, et al.
JAMA Network Open|March 20, 2025
Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal CancerShahla Bari, Marco Matejcic, Richard D Kim, et al.
American Journal of Clinical Oncology|November 3, 2015
Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical TrialsAaron Denson, Nancy Burke, Georgine Wapinsky, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2022
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancerRichard D Kim, Bence P Kovari, Maria Martinez, et al.
JAMA Network Open|June 26, 2023
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal CancerLingbin Meng, Ram Thapa, Maria G Delgado, et al.
JAMA Oncology|May 1, 2020
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerRichard D Kim, Vincent Chung, Olatunji B Alese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
Cancers|June 13, 2025
Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter StudyMaen Abdelrahim, Abdullah Esmail, Richard D Kim, et al.
Pageof 6